ORAGENICS, INC. ANNOUNCES COMPLETION OF ENROLLMENT OF ITS PHASE 2 CLINICAL TRIAL FOR AG013

INC. ANNOUNCES COMPLETION OF ENROLLMENT OF ITS PHASE 2 CLINICAL

TRIAL FOR AG013 IN ORAL MUCOSITIS

Fla., December 2, 2019 - Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious

diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind,

randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy to use oral rinsing system designed

to prevent and treat OM.

ongoing Phase 2 trial is a double-blind, placebo-controlled, two-arm, multi-country, multi-center trial, in which 200 patients

have been randomized in a 1:1 ratio to receive either AG013 ("dapatifagene navolactibac") or a placebo. The

purpose of the study (NCT03234465) is to evaluate the safety, tolerability and efficacy of topically administered AG013 compared

to placebo for reducing the incidence and severity of OM in patients undergoing traditional chemoradiation (CRT) for the treatment

of head and neck cancer (HNC). Key measures include duration, time to development, and overall incidence of OM (using a World

Health Organization (WHO) scale) during the active treatment phase, which begins from the start of chemoradiation therapy and

ends two weeks following its completion.

Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, stated, "The completion of enrollment represents the

next key operational milestone in the continued progress toward completion of this important clinical trial evaluating the clinical

efficacy and safety of our AG013 product candidate. Oral mucositis is a debilitating condition in head and neck cancer patients

receiving chemoradiation and it is our belief that AG013 will provide relief for patients at risk for development of this condition

and allow them to successfully complete their cancer treatment regimen." Dr. Joslyn continued "With the achievement

of this significant corporate milestone, we remain on track to report results from this study in early 2020."

results in a painful inflammation and mucosal ulceration in the lining of the oral cavity, throat and esophagus and is one of

the most commonly reported adverse events associated with cancer chemotherapy and radiation therapy. Approximately 770,000 patients

annually in the U.S. are at an increased risk of developing OM according to cancer statistics provided by the Center for Disease

Control in 2017. OM has a negative effect on patient well-being and, if severe, negatively affects adherence to a patient's

cancer treatment regimen and adversely impacts a range of collateral health outcomes, all resulting in increased use of resources

and cost of care. Virtually all patients who receive standard concomitant CRT regimens for the treatment of HNCs develop ulcerative

OM (UOM: WHO Grade 2). Even more significant is the consistent observation that severe OM (WHO Grade 3) is noted in more

than two-thirds of the same patient population. At present, there are no drugs approved to prevent the condition broadly and current

therapies are primarily palliative in nature, only addressing symptom relief but not treating the underlying causes of the condition.

which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is

an ActoBio Therapeutics Inc. candidate formulated to deliver the therapeutic molecule, human Trefoil Factor 1, to the mucosal

tissues in the oral cavity in a convenient oral rinsing solution system. Trefoil Factors are a class of peptides involved in the

protection of gastrointestinal tissues against mucosal damage and play an important role in these tissues' subsequent regeneration.

The human Trefoil Factor1 is delivered to the oral cavity using a genetically modified Lactococcus lacti bacteria, commonly

found in dairy products, engineered to continuously delivery the human protein . The compound was designed by the Company's

strategic partner, ActoBio Therapeutics Inc., a wholly-owned subsidiary of Intrexon Corporation (NYSE: XON).

are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral

mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries.

The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant

strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity,

throat, and esophagus.

more information about Oragenics, please visit www.oragenics.com.

Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release

includes forward-looking statements that reflect management's current views with respect to future events and performance.

These forward-looking statements are based on management's beliefs and assumptions and information currently available.

The words "believe," "expect," "anticipate," "intend," "estimate,"

"project" and similar expressions that do not relate solely to historical matters identify forward-looking statements.

Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties,

and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements.

These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange

Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with

respect to the matters described herein.

Sullivan, 813-286-7900